apatinib

epidermal growth factor receptor ; Homo sapiens







26 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33994798 Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report. 2021 1
2 34026823 Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. 2021 2
3 34033974 Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). 2021 Sep 2
4 34761117 Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report. 2021 1
5 31231786 A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. 2020 Apr 3
6 31918452 Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185). 2020 Mar 1
7 32351894 Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases. 2020 2
8 32508029 Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. 2020 Jun 4
9 32642151 Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. 2020 May 3
10 30608421 Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. 2019 Jan 1
11 30702616 Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report. 2019 Feb 1
12 30706337 Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. 2019 Aug 2
13 31073278 Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. 2019 1
14 31570733 Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial. 2019 Sep 30 2
15 31699150 The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). 2019 Nov 7 3
16 29467959 Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. 2018 Jan 23 4
17 29575765 Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. 2018 May 3
18 29740957 EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes. 2018 Jul 2
19 30003733 An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving gene(s). 2018 May-Jun 1
20 30038504 Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. 2018 1
21 30170427 Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis. 2018 Aug 2
22 30344715 Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma. 2018 Nov 1
23 28176910 Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. 2017 2
24 28490886 Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. 2017 3
25 28822888 Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. 2017 Oct 6
26 29029508 Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. 2017 Sep 12 3